Our News

Press Releases & Media

May 26, 2022

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Read More
April 28, 2022

Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day

Read More
April 25, 2022

FDA Grants ODD Status to TTI-101 for Hepatocellular Carcinoma

Read More
April 21, 2022

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

Read More
December 27, 2021

These Were the Top 5 Venture Capital Deals in Houston in 2021

Read More
September 27, 2021

Fierce Biotech Names Tvardi Therapeutics as One of its “Fierce 15” Biotech Companies of 2021

Read More
September 27, 2021

Special Report: Tvardi Therapeutics Fierce Biotech’s Fierce 15 2021

Read More
June 23, 2021

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

Read More
June 23, 2021

Houston-Based Tvardi Therapeutics Raises $74 Million in Series B Funding

Read More

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.

Accept & Close